Molecular regulation of cholesterol metabolism: HDL-based intervention through drugs and diet

Indian Journal of Experimental Biology

Volumn 51, Issue 11, 2013, Pages 885-894

  Rai, Amit Kumar ^a   Debetto, Patrizia ^a   Dabbeni Sala, Federica ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cardiovascular disease; Cholesterol; Drugs interfering with RCT; HDL; Nutrition

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

BIOSYNTHESIS; DIET; DIET THERAPY; ENDOCYTOSIS; HUMAN; HYPERCHOLESTEROLEMIA; METABOLISM; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL, HDL; DIET; ENDOCYTOSIS; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 84887536452     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Goldstein J L & Brown M S, Regulation of the mevalonate pathway, Nature, 343 (1990) 425.
2. Von Eckardstein A, Nofer JR, & Assmann G, Arterioscler Thromb Vasc Biol, 21 (2001) 13.
3. Heart protection study collaborative group, Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360 (2002) 7.
4. Badimon JJ, Badimon L, & Fuster V, Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit, J Clin Invest, 85 (1990) 1234.
5. Lewis GF, Determinants of plasma HDL concentrations and reverse cholesterol transport, Curr Opin Cardiol, 21 (2006) 345.
6. Puranik R, Bao S, Nobecourt E, Nicholls S J, Dusting G J, Barter P J, Celermajer D S & Rye K A, Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo, Atherosclerosis, 196 (2008) 240.
7. Bowry V W, Stanley K K, & Stocker R, High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors, Proc Natl Acad Sci 89 (1992) 10316.
8. Viswambharan H, Ming X F, Zhu S, Hubsch A, Lerch P, Vergères G, Rusconi S & Yang Z, Reconstituted high-density lipoprotein inhibits thrombin induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase, Circ Res, 94 (2004) 918.
9. Nofer J R, Brodde M F & Kehrel B E, High-density lipoproteins, platelets and the pathogenesis of atherosclerosis, Clin Exp Pharmacol Physiol, 37 (2010) 726.
10. Hersberger M & Von Eckardstein A, Low High- Density Lipoprotein Cholesterol. Physiological background, Clinical importance and drug treatment, Drugs, 63 (2003) 1907.
11. Larrede S, Quinn C M, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim M-J, Van Eck M, Couvert P, Carrie A, Giral P, Chapman M J, Guerin M, & Le Goff W. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent, Arterioscler Thromb Vasc Biol, 29 (2009) 193011.
12. Martinez L O, Jacquet S, Esteve J P, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker J E, Terce F, Collet X, Perret B, & Barbaras R, Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis, Nature, 42 (2003) 175.
13. Dabbeni-Sala F, Rai A K & Lippe G, F0F1 ATP synthase- A fascinating challenge for proteomics, Human diseases and proteomics, (InTech Pub, Croatia), 2012, 161.
14. Giorgio V, Bisetto E, Soriano ME, Dabbeni-Sala F, Basso E, Petronilli V, Forte MA, Bernardi P, & Lippe G, Cyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complex, J Biol Chem, 284 (2009) 33982.
15. Giorgio V, Bisetto E, Franca R, Harris D A, Passamonti S, & Lippe G, The ectopic F0F1 ATP synthase of rat liver is modulated in acute cholestasis by the inhibitor protein IF1, J Bioenerg Biomembr, 42 (2010) 117.
16. Genoux A, Pons V, Radojkovic C, Roux-Dalvai F, Combes G, Rolland C, Malet N, Monsarrat B, Lopez F, Ruidavets J B, Perret B & Martinez L O, Mitochondrial Inhibitory Factor 1 (IF1) Is Present in Human Serum & Is Positively Correlated with HDL Cholesterol, PLoS ONE, 6 (2011) 23949.
17. Cavelier C, Ohnsorg P M, Rohrer L, & Eckardstein A V, The beta Chain of Cell Surface F0F1 ATPase Modulates ApoA-I & HDL transcytosis through aortic endothelial cells, Arterioscler Thromb Vasc Biol, 32 (2012) 131.
18. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, & Yvan-Charvet L, cholesterol efflux & atheroprotection: advancing the concept of reverse cholesterol transport, Circulation, 125 (2012) 1905.
19. Redondo S, Martínez-González J, Urraca C, & Tejerina T, Emerging therapeutic strategies to enhance HDL function, Lipids in Health and Disease, 10 (2011) 175.
20. Franceschini G, Sirtori C R, Capurso A, Weisgraber K H, & Mahley R W, A-I Milano apoprotein: Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family, J Clin Invest, 66 (1980) 892.
21. Cimmino G, Ibanez B, Vilahur G, Speidl W S, Fuster V, Badimon L & Badimon J J, Up-regulation of reverse cholesterol transport key players & rescue from global inflammation by ApoA-I(Milano), J Cell Mol Med, 133 (2009) 226.
22. Nissen S E, Tardif J C, Nicholls S J, Revkin J H, Shear C L, Duggan W T, Ruzyllo W, Bachinsky W B, Lasala G P, & Tuzcu E M, Effect of torcetrapib on the progression of coronary atherosclerosis, N Engl J Med, 356 (2007) 1304.
23. Barter P J, Caulfield M, Eriksson M, Grundy S M, Kastelein J J, Komajda M, Lopez-Sendon J, Mosca L, Tardif J C, Waters D D, Shear C L, Revkin J H, Buhr K A, Fisher M R, Tall A R, & Brewer B, Effects of torcetrapib in patients at high risk for coronary events, N Engl J Med, 357 (2007) 2109.
24. Psaty B M & Lumley T, Surrogate end points & FDA approval: a tale of 2 lipid-altering drugs, JAMA, 299 (2008) 1474.
25. Chapman M J, Le Goff W, Guerin M, & Kontush A, Cholesteryl ester transferprotein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors, Eur Heart J, 31 (2010) 49.
26. Stroes E S, Kastelein J J, Bénardeau A, Kuhlmann O, Blum D, Campos L A, Clerc R G, & Nisor E J, Dalcetrapib: no offtarget toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats, Br J Pharmacol, 158 (2009) 1763.
27. Krishna R, Anderson M S, Bergman A J, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield D M, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener K M & Wagner J A, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients withdyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies, Lancet, 370 (2007) 1907.
28. Ricote M, Valledor A F, & Glass C K, Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis, Arterioscler Thromb Vasc Biol, 24 (2004) 230.
29. Yu L, York J, von Bergmann K, Lutjohann D, Cohen J C, & Hobbs H H, Stimulation of cholesterol excretion by the liver × receptor agonist requires ATP-binding cassette transporters G5 and G8, J Biol Chem, 278 (2003) 15565.
30. Venkateswaran A, Laffitte B A, Joseph S B, Mak P A, Wilpitz D C, Edwards P A, & Tontonoz P, Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha, Proc Natl Acad Sci, 97 (2000) 12097.
31. Naik S U, Wang X, Da Silva J S, Jaye M, Macphee C H, Reilly M P, Billheimer J T, Rothblat G H, & Rader D J, Pharmacological activation of liver × receptors promotes reverse cholesterol transport in vivo, Circulation, 11 (2006) 390.
32. Peng D, Hiipakka R A, Xie J T, Dai Q, Kokontis J M, Reardon C A, Getz G S, & Liao S, A novel potent synthetic steroidal liver × receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice, Br J Pharmacol, 162 (2011) 1792.
33. Cha J Y & Repa J J, The liver X receptor (LXR) & hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR, J Biol Chem, 282 (2007) 743.
34. Braun A, Trigatti B L, Post M J, Sato K, Simons M, Edelberg J M, Rosenberg R D, Schrenzel M, & Krieger M, Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice, Circ Res, 90 (2002) 270.
35. Masson D, Koseki M, Ishibashi M, Larson C J, Miller S G, King B D & Tall A R, Increased HDL cholesterol and apoAI in humans and mice treated with a novel SR-BI inhibitor, Arterioscler Thromb Vasc Biol, 29 (2009) 2054.
36. Zhang L H, Kamanna V S, Zhang M C & Kashyap M L, Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL, J Lip Res, 49 (2008) 1195.
37. Nijstad N, Gautier T, Briand F, Rader D J, & Tietge U J F, biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice, Gastroenterol, 140 (2011) 1043.
38. van der Velde A E, Vrins C L, & van den Oever K, Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice, Gastroenterol, 133 (2007) 967.
39. Wang L Juan & Song B L, Niemann-Pick C1-Like 1 and cholesterol uptake, Biochim Biophys Acta, 1821 (2012) 964.
40. NIH Publication No. 02-5215, September 2002.
41. Mensink R P, Ebbing S, Lindhout M, Plat J, & van Heugten M M, Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations, Atherosclerosis, 160 (2002) 205.
42. Katan M B, Grundy S M, Jones P, Law M, Miettinen T A, & Paoletti R, Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels, Mayo Clin Proc, 78 (2003) 965.
43. Trautwein E A, Duchateau G S M J E, Lin Y, Mel'nikov S M, Molhuizen H O F, & Ntanios F Y, Proposed mechanisms of cholesterol-lowering action of plant sterols, Eur J Lipid Sci Technol, 105 (2003) 171.
44. Brauner R, Johannes C, Ploessl F, Bracher F, & Lorenz R L, Phytosterols Reduce Cholesterol Absorption byInhibition of 27-Hydroxycholesterol Generation,Liver X Receptor a Activation, and Expression of the Basolateral Sterol Exporter ATP-Binding Cassette A1 in Caco-2 Enterocytes, J Nutr, 142 (2012) 981.
45. Pavlović N, Stankov K, & Mikov M, Probiotics-interactions with bile acids and impact on cholesterol metabolism, Appl Biochem Biotechnol, 12 (2010) 9904.
46. WHO, Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria, 2001.
47. Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Ashok K, Chakraborty C, Singh B, Marotta F, Jain S & Yadav H, Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases, Exp Diabetes Res, (2012) 14.
48. Ooi L G & Liong M T, Cholesterol-lowering effects of probiotics & prebiotics: A review of in vivo and in vitro findings, Int J Mol Sci, 11 (2010) 2499.
49. Wong, J. M, de Souza R, Kendall C W, Emam A, & Jenkins D J, Colonic Health: Fermentation and short chain fatty acids, J Clin Gastroenerol, 40 (2006) 235.
50. Huang Y & Zheng Y, The probiotic Lactobacillus acidophilus reduces cholesterol absorption through the downregulation of Niemann-Pick C1-like 1 in Caco-2 cells, Br J Nutr, 103 (2010) 473.
51. Duval C, Touche V, Tailleux A, Fruchart J C, Fievet C, Clavey V, Staels B, & Lestavel S, Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine, Biochem Biophys Res Commun, 340 (2006) 1259.